ADC Therapeutics SA (NYSE:ADCT) Q3 2023 Earnings Call Transcript

We see that pattern is very similar. And that is what opens up the opportunity for a product like ZYNLONTA in the community where it is an off-the-shelf option that is accessible and provides a rapid response for patients who need it. You had a question around CAR-T in the second line. We do see an increase in the utilization of CAR-T as it becomes standard of care in the second line. But again, while it is increasing, we also continue to hear from physicians that is still a challenge for patients to get access to these complex therapies. There are different stats that are shared, whether it’s 25%, 35% of patients who will get access to them. And then the — let’s see, the last question, when do we feel it will be a good point to give guidance.

Ameet Mallik: Yes. I mean at this point, we’re not adding guidance. Brian, but just one more thing I just want to say about the bispecifics. One is not every patient can tolerate a bispecific after the CAR-T. I mean once you fail on a CAR-T, so you’re pretty sick, those patients are pretty sick at this point. So for those who could tolerate it, I think they’re likely going to get a bispecific in that academic center, but some patients can’t. And a treatment like ZYNLONTA is about, a cleaner safety profile and also very fast action, a very fast time to assess response is critical for those patients. But also the majority of patients are going to progress post the bispecific. So also in the fourth-line setting, that starts to open up as well.

So there’s clearly a place for ZYNLONTA in academic setting. It’s going to be less than what it was before, and we knew that was going to happen, which is why our strategy has been to adjust the model to capitalize on the bigger opportunity, which is growth in the community.

Brian Cheng: Great. Thank you so much. That was very helpful. Thank you.

Operator: Thank you. There are no further questions at this time, and I will now turn the call back to Ameet.

Ameet Mallik: Well, I just want to thank everyone for joining. Thanks for your interest in the company, and thanks for joining the quarterly update. We look forward to keeping you updated on our progress. And I hope everyone has a great day. Thank you.

Operator: This concludes our programs and you may now disconnect. Thank you.